Videos

Ruben A. Mesa, MD, discusses emerging therapies in myelofibrosis.








Dr. Mesa on Emerging Therapies in Myelofibrosis 

Ruben A. Mesa, MD, discusses the emergence of JAK inhibitors in myelofibrosis. 








Dr. Mesa on the Emergence of JAK Inhibitors in Myelofibrosis

Ruben A. Mesa, MD, discusses current data with ruxolitinib and fedratinib in myelofibrosis.

Dr. Mesa on Current Data With Ruxolitinib and Fedratinib in Myelofibrosis

Ruben A. Mesa, MD, discusses accrual considerations in myeloproliferative neoplasms  clinical trials. 

Dr. Mesa on Accrual Considerations in MPN Clinical Trials  

Ruben A. Mesa, MD, discusses the importance of developing racially inclusive clinical trials in myeloproliferative neoplasms.  



Dr. Mesa on Developing Racially Inclusive Clinical Trials in MPNs 

Ruben A. Mesa, MD, discusses racial disparities in clinical trials for patients with myeloproliferative neoplasms, myelodysplastic syndrome, and acute myeloid leukemia.

UT Health San Antonio MD Anderson Cancer Center

Latest from UT Health San Antonio MD Anderson Cancer Center

New content coming soon, please check back later.